- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Vytorin Study Causes Media Stir, but Are the Concerns Justified?
Unlike Vioxx, Vytorin works exactly as explained in its now-famous food-and-family ads. So why are people up in arms against the drug? Experts ponder what went wrong.
Merck and Schering-Plough's announcement last week that Vytorin did not show any evidence of reducing fatty plaque buildup in veins and arteries stirred up a lot of complaints from industry pundits who felt that the public was misled by pharma.
There's only one hitch: The two pharma companies never stated that the drug, a cholesterol-lowering combination of Zocor and Zetia, had an effect on plaque.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.
